LXR agonists for the treatment of atherosclerosis

Current Opinion in Investigational Drugs

Volumn 4, Issue 9, 2003, Pages 1053-1058

  Jaye, Michael ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Atherosclerosis; Lipogenesis; LXR; Macrophage; Modulator; Structure

Indexed keywords

ABC TRANSPORTER; AGN 34; ANTIINFLAMMATORY AGENT; CELL NUCLEUS RECEPTOR; CHOLESTEROL; CHOLESTEROL EPOXIDE; GW 683965A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA AGONIST; LIVER X RECEPTOR BETA AGONIST; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; RETINOID DERIVATIVE; STEROL; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CELL TRANSPORT; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; LIPOGENESIS; LIVER; MACROPHAGE; NONHUMAN; REVIEW; SENSOR; SMALL INTESTINE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; MACROPHAGES; MOLECULAR STRUCTURE; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 0142152235     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Glomset JA: The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res (1968) 9(2):155-167.
2. Serfaty-Lacrosniere C, Civeira F, Lanzberg A, Isaia P, Berg J, Janus ED, Smith MP Jr, Pritchard PH, Frohlich J, Lees RS et al: Homozygous Tangier disease and cardiovascular disease. Atherosclerosis (1994) 107(1):85-98.
3. Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, Inaba T: T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett (2003) 536(1-3):6-11.
4. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, Tran J et al: Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA (2002) 99(11):7604-7609. First demonstration that a synthetic LXR agonist, the tertiary amine GW-683965A, inhibits atherosclerosis in both LDLr-/- and apoE-/- mice.
5. Plosch T, Kok T, Bloks VW, Smith MJ, Havinga R, Chimini G, Groen AK, Kuipers F: Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J Biol Chem (2002) 277(37):33870-33877.
6. Yu L, York J, Van Bergmann K, Lutjohann D, Cohen JC, Hobbs HH: Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem (2003) 278(18):15565-15570.
7. Lee MH, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, Kojima H, Allikmets R, Sakuma N, Pegoraro R, Srivastava AK et al: Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet (2001) 27(1):79-83.
8. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science (2000) 290(5497):1771-1775.
9. Graf GA, Li WP, Gerard RD, Gelissen I, White A, Cohen JC, Hobbs HH: Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J Clin Invest (2002) 110(5):659-669.
10. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA, Wilson TM: Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem (1997) 272(6):3137-3140. Demonstration that oxysterols are agonists for the orphan nuclear receptors LXRα and LXRβ and identification of an LXRE in the proximal promoter of the rat cyp7a gene, suggesting a new signaling pathway for the regulation of cholesterol homeostasis by oxysterol LXR agonists.
11. Chiang JY, Kimmel R, Stroup D: Regulation of cholesterol 7α-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRα). Gene (2001) 262(1-2):257-265.
12. Fowler AJ, Sheu MY, Schmuth M, Kao J, Fluhr JW, Rhein L, Collins JL, Willson TM, Mangelsdorf DJ, Elias PM, Feingold KR: Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: Liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol (2003) 120(2):246-255. This paper, together with reference, demonstrates anti-inflammatory properties of synthetic LXR agonists in murine models.
13. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P: Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med (2003) 9(2):213-219. This paper reports the upregulation of genes involved in lipid metabolism and inhibition of expression of inflammatory genes, including inducible nitric oxide synthase, monocyte chemoattractant protein-1, and cyclooxygenase-2 by GW-683965A treatment of activated murine macrophages. Evidence that the anti-inflammatory effect of LXR is mediated by inhibition of nuclear factor-κB activation is shown.
14. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD et al: Role of LXRs in control of lipogenesis. Genes Dev (2000) 14(22):2831-2838. This paper describes the characterization of the synthetic LXR agonist T-0901317 and demonstration of its lipogenic effect and upregulation of hepatic SREBP-1c and other lipogenic genes (FAS, ACC-1 and SCD-1) in mice and hamsters.
15. Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, Bloks VW, Van Der Sluijs FH, Havekes LM, Romijn JA, Verkade HJ, Kuipers F: Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem (2002) 277(37):34182-34190.
16. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ: Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell (1998) 93(5):693-704. This paper demonstrates that LXRα knockout mice on a cholesterol-containing diet fail to upregulate hepatic Cyp7a expression, resulting in massive cholesterol accumulation in the liver, impaired hepatic function and lethality. Failure of LXRβ to compensate for LXRα and normal phenotype of LXRβ null mice highlights distinct roles of hepatic LXRs.
17. Torchia J, Glass C, Rosenfeld MG: Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol (1998) 10(3):373-383.
18. Xu L, Glass CK, Rosenfeld MG: Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev (1999) 9(2):140-147.
19. Spencer TA, Li D, Russel JS, Collins JL, Bledsoe RK, Consler TG, Moore LB, Galardi CM, McKee DD, Moore JT, Watson MA et al: Pharmacophore analysis of the nuclear oxysterol receptor LXRα. J Med Chem (2001) 44(6):886-897.
20. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangesldorf DJ: An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature (1996) 383(6602):728-731.
21. Zhang Z, Li D, Blanchard DE, Lear SR, Erickson SK, Spencer TA: Key regulatory oxysterols in liver: Analysis as Δ4-3-ketone derivatives by HPLC and response to physiological perturbations. J Lipid Res (2001) 42(4):649-658.
22. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lung EG: 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem (2001) 276(42):38378-38387.
23. Song C, Liao S: Cholestenoic acid is a naturally occurring ligand for liver X receptor α. Endocrinology (2000) 141(11):4180-4184.
24. Song C, Hiipakka RA, Liao S: Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: Implications for the development and treatment of atherosclerosis. Steroids (2001) 66(6):473-479.
25. Gan X, Kaplan R, Menke JG, MacNaul K, Chen Y, Sparrow CP, Zhou G, Wright SD, Cai TQ: Dual mechanisms of ABCA1 regulation by geranylgeranyl pyrophosphate. J Biol Chem (2001) 276(52):48702-48708.
26. Pawar A, Xu J, Jerks E, Mangelsdorf DJ, Jump DB: Fatty acid regulation of liver X receptors (LXR) and peroxisome proliferator-activated receptor α (PPARα) in HEK293 cells. J Biol Chem (2002) 277(42):39243-39250.
27. Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, Corey EJ, Mangelsdorf DJ: Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ. Proc Natl Acad Sci USA (1999) 96(1):266-271.
28. Repa JJT, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, Shan B, Heyman RA, Dietschy JM, Mangelsdorf DJ: Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science (2000) 289(5484):1524-1529. This paper reports that treatment of mice with T-0901317 decreases cholesterol absorption. This is attributed to upregulated ABCA1 expression in small intestine, however, subsequent discoveries (see references [5-9]) indicate that this effect is due to upregulated intestinal ABCG5 and ABCG8 expression. Studies in peritoneal macrophages from knockout mice demonstrate upregulation of ABCA1 mediated by both LXR subtypes.
29. Sparrow CP, Baffici J, Lam MH, Lund EG, Adams AD, Fu X, Hayes N, Jones AB, MacNaul KL, Ondeyka J Singh S et al: A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem (2002) 277(12):10021-10027.
30. Collins JL, Fivush AM, Watson MA, Galardi CM, Lewis MC, Moore LB, Parks DJ, Wilson JG, Tippin TK, Binz JG, Plunket KD et al: Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem (2002) 45(10):1963-1966.
31. Menke JG, MacNaul KL, Hayes NS, Baffic J, Chao YS, Elbrecht A, Kelly LJ, Lam MH, Schmidt A, Sahoo S, Wang J et al: A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7α-hydroxylase (CYP7a). Endocrinology (2002) 143(7):2548-2558.
32. Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Bjorkhem, I, Pettersson S, Gustafsson JA: Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice. J Clin Invest (2001) 107(5):565-573. In contrast to LXRα-deficient micr (see reference), LXRβ null mice are resistant to dietary cholesterol.
33. Zhang Y, Repa JJ, Gauthier K, Mangelsdorf DJ: Regulation of lipoprotein lipase by the oxysterol receptors, LXRα and LXRβ. J Biol Chem (2001) 276(46) 43018-43024. Studies in cholesterol fed and T-0901317-treated wild-type, LXRα- and LXRβ-deficient mice show that hepatic LPL is upregulated preferentially by LXRα. LPL upregulation is mediated by LXRE in intron 1, which shows higher activity with LXRα versus LXRβ in gel shift and transient transfection experiments.
34. Babaev VR, Patel MB, Semenkovich CF, Fazio S, Linton MF: Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J Biol Chem (2000) 275(34):26293-26299.
35. Wilson K, Fry GL, Chappell DA, Sigmund CD, Medh JD: Macrophage-specific expression of human lipoprotein lipase accelerates atherosclerosis in transgenic apolipoprotein E knockout mice but not in C57BL/6 mice. Arterioscler Thromb Vasc Biol (2001) 21(11):1809-1815.
36. Mak PA, Laffitte BA, Desrumaux C, Joseph SB, Curtiss LK, Mangelsdorf DJ, Tontonoz P, Edwards PA: Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors α and β. J Biol Chem (2002) 277(35):31900-31908.
37. Kaplan R, Zhang T, Hernandez M, Gan FX, Wright SD, Waters MG, Cai TQ: Regulation of the angiopoietin-like protein 3 gene by LXR. J Lipid Res (2003) 44(1):136-143.
38. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, Collins JL, Osborne TF, Tontonoz P: Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem (2002) 277(13):11019-11025.
39. Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, MatsuzakaT, Okazaki H, Tamura Y, Lizuka Y, Ohashi K, Osuga J et al: Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol (2001) 21(9):2991-3000.
40. Schuster GU, Parini P, Wang L, Alberti S, Steffensen KR, Hansson GK, Angelin B, Gustafsson JA: Accumulation of foam cells in liver X receptor-deficient mice. Circulation (2002) 106(9):1147-1153.
41. Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, Daige CL, Thomas D, Heyman RA, Mangelsdorf DJ, Wang X et al: Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA (2002) 99(18):11896-11901. Increased atherosclerosis in LDLr-/- or apoE-/- mice transplanted with bone marrow from doubly deficient LXRα/β mice, demonstrating macrophage LXRs as inhibitors of atherosclerosis.
42. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P: Autoregulation of the human liver X receptor α promoter. Mol Cell Biol (2001) 21(22):7558-7568.
43. Whitney KD, Watson MA, Goodwin B, Galardi CM, Maglich JM, Wilson JG, Willson TM, Collins JL, Kliewer SA: Liver X receptor (LXR) regulation of the LXRα gene in human macrophages. J Biol Chem (2001) 276(47):43509-43515.
44. Venkateswaran A, Repa JJ, Lobaccaro JM, Bronson A, Mangelsdorf DJ, Edwards PA: Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem (2000) 275(19):14700-14707.
45. Klucken J, Buchler C, Orso E, Kaminski WE, Porsch-Ozcurumez M, Liebisch G, Kapinsky M, Diederich W, Drobnik W, Dean M, Allikmets R et al: ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA (2002) 97(2):817-822. This paper reports the regulated expression of ABCG1 by cholesterol loading of human macrophages and its role in cellular cholesterol efflux by antisense knockdown.
46. Van Eck M, Bos IS, Kaminski WE, Orso E, Rothe G, Twisk J, Bottcher A, Van Amersfoort ES, Christiansen-Weber TA, Fung-Leung WP, Van Berkel TJ et al: Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci USA (2002) 99(9):6298-6303. This paper, together with reference, demonstrates by bone marrow transplantation that selective inactivatio n of leukoocyte ABCA1 expression increases the development of atherosclerosis in apoE-/- and LDLr-/- mice without altering plasma HDL-C levels.
47. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, Coskran T, Haghpassand M, Francone OL: Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol (2002) 22(4):630-637. This paper, together with reference, demonstrates by bone marrow transplantation that selective inactivation of leukocyte ABCA1 expression increases the development of atherosclerosis in apoE-/- and LDLr-/- mice without altering plasma HDL-C levels.
48. Castrillo A, Joseph SB, Marathe C, Mangesldorf DJ, Tontonoz P: Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J Biol Chem (2003) 278(12):10443-10449.
49. Hu X, Li S, Wu J, Xia C, Lala DS: Liver X receptors interact with corepressors to regulate gene expression. Mol Endocrinol (2003) 17(6):1019-1026.
50. Shang Y, Brown M: Molecular determinants for the tissue specificity of SERMs. Science (2002) 295(5564):2465-2468.
51. Dussault I, Beard R, Lin M, Hollister K, Chen J, Xiao J-H, Chandraratna R, Forman BM: Identification of gene-selective modulators of the bile acid receptor FXR. J Biol Chem (2003) 278(9):7027-7033.
52. Cui J, Huang L, Zhao A, Lew J-L, Yu J, Sahoo S, Meinke PT, Royo I, Pelaez F, Wright SD: Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem (2003) 278(12):10214-10220.
53. Thomas J, Bramlett KS, Montrose C, Foxworthy P, Eacho PI, McCann D, Cao G, Kiefer A, McCowan J, Yu K-I, Grese T et al: A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor α (PPARα) versus liver X receptor. J Biol Chem (2003) 278(4):2403-2410.
54. Williams SP, Bledsoe RK, Collins JL, Boggs S, Lambert MH, Miller AB, Moore JT, McKee DD, Moore L, Nichols J, Parks D et al: X-ray crystal structure of the liver X receptor β ligand binding domain: Regulation by a histidine-tryptophan switch. J Biol Chem (2003) 278(29):27138-27143. This paper, together with reference, reports co-crystal structures of LXRβ with synthetic and natural LXR agonists, revealing a large, flexible ligand binding pocket and mechanism of ligand-induced receptor activation.
55. Farnegardh M, Bonn T, Sun S, Ljunggren J, Ahola H, Wilhelmsson A, Gustafsson J-A, Carlquist M: The three dimensional structure of the liver X receptor β reveals a flexible ligand binding pocket that can accommodate fundamentally different ligands. J Biol Chem (2003) 278:10. 1074/jbc.M304842200/. This paper, together with reference, reports co-crystal structures of LXRβ with synthetic and natural LXR agonists, revealing a large, flexible ligand binding pocket and mechanism of ligand-induced receptor activation.